IL158202A0 - Aripiprazole oral solution - Google Patents

Aripiprazole oral solution

Info

Publication number
IL158202A0
IL158202A0 IL15820202A IL15820202A IL158202A0 IL 158202 A0 IL158202 A0 IL 158202A0 IL 15820202 A IL15820202 A IL 15820202A IL 15820202 A IL15820202 A IL 15820202A IL 158202 A0 IL158202 A0 IL 158202A0
Authority
IL
Israel
Prior art keywords
oral solution
aripiprazole oral
aripiprazole
solution
oral
Prior art date
Application number
IL15820202A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL158202(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL158202A0 publication Critical patent/IL158202A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15820202A 2001-04-25 2002-04-24 Aripiprazole oral solution IL158202A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28671801P 2001-04-25 2001-04-25
PCT/US2002/013048 WO2002085366A1 (en) 2001-04-25 2002-04-24 Aripiprazole oral solution

Publications (1)

Publication Number Publication Date
IL158202A0 true IL158202A0 (en) 2004-05-12

Family

ID=23099862

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15820202A IL158202A0 (en) 2001-04-25 2002-04-24 Aripiprazole oral solution
IL158202A IL158202A (en) 2001-04-25 2003-10-01 Oriprazole oral solution

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158202A IL158202A (en) 2001-04-25 2003-10-01 Oriprazole oral solution

Country Status (36)

Country Link
US (1) US6977257B2 (sr)
EP (2) EP1381367B1 (sr)
JP (1) JP4401077B2 (sr)
KR (1) KR100909329B1 (sr)
CN (1) CN1512884B (sr)
AR (1) AR033168A1 (sr)
AT (1) ATE537831T1 (sr)
AU (1) AU2002254722B2 (sr)
BG (1) BG66177B1 (sr)
BR (1) BR0208986A (sr)
CA (1) CA2445276C (sr)
CY (1) CY1112606T1 (sr)
CZ (1) CZ306181B6 (sr)
DK (1) DK1381367T3 (sr)
EE (1) EE05581B1 (sr)
ES (1) ES2377855T3 (sr)
GE (1) GEP20053602B (sr)
HR (1) HRP20030870B1 (sr)
HU (1) HU230456B1 (sr)
IL (2) IL158202A0 (sr)
IS (1) IS2863B (sr)
MX (1) MXPA03009728A (sr)
MY (1) MY129350A (sr)
NO (1) NO324606B1 (sr)
NZ (1) NZ528550A (sr)
PE (1) PE20021086A1 (sr)
PL (1) PL206882B1 (sr)
PT (1) PT1381367E (sr)
RS (1) RS52082B (sr)
RU (1) RU2295960C2 (sr)
SK (1) SK287948B6 (sr)
TW (1) TWI337865B (sr)
UA (1) UA76144C2 (sr)
UY (1) UY27273A1 (sr)
WO (1) WO2002085366A1 (sr)
ZA (1) ZA200307797B (sr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
DE60327225D1 (de) 2002-08-20 2009-05-28 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
US7691880B2 (en) * 2003-10-08 2010-04-06 Mallinckrodt Inc. Methylphenidate solution and associated methods of administration and production
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
AU2005205933B2 (en) * 2004-01-21 2010-02-18 Elanco Animal Health Ireland Limited Mitratapide oral solution
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
DE602006006536D1 (de) * 2006-01-05 2009-06-10 Teva Pharma Trockene Aripiprazolformulierungen
DE602006004694D1 (de) * 2006-01-05 2009-02-26 Teva Pharma Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
EP2041304B1 (en) 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
JP4879349B2 (ja) * 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
WO2010146872A1 (ja) * 2009-06-19 2010-12-23 株式会社メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102846616B (zh) * 2011-06-27 2015-05-06 上海中西制药有限公司 一种阿立哌唑制剂及其制备方法
GB2505860B (en) * 2011-06-27 2018-10-31 Shanghai Zhongxi Pharmaceutical Corp Aripiprazole medicament formulation and preparation method therefor
AR088372A1 (es) * 2011-10-19 2014-05-28 Otsuka Pharma Co Ltd Solucion para administracion oral
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
WO2014002553A1 (ja) 2012-06-29 2014-01-03 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
KR101571670B1 (ko) * 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
EP3718536A1 (en) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
JP6248112B2 (ja) * 2012-09-26 2017-12-13 ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ アピキサバン液体製剤
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
WO2014059363A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals Llc Oral solution formulations of aripiprazole
EP2908859B1 (en) * 2012-10-16 2017-05-17 Arven Ilac Sanayi ve Ticaret A.S. Aripiprazole formulations
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
EP3119399A4 (en) 2014-03-20 2017-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) * 2015-06-12 2016-12-07 高田製薬株式会社 アリピプラゾール含有内用液剤
WO2017025930A1 (en) 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CN108434146A (zh) * 2017-02-16 2018-08-24 天津国际生物医药联合研究院 一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 阿立哌唑口服溶液及其制备方法
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN112666267B (zh) * 2019-10-15 2023-09-26 上海上药中西制药有限公司 一种阿立哌唑药品有关物质的检测方法
JP2023173950A (ja) * 2022-05-27 2023-12-07 同仁医薬化工株式会社 経口液剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU843739A3 (ru) 1978-02-17 1981-06-30 Карл Томэ Гмбх (Фирма) Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja) 1982-09-29 1984-04-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体−シクロデキストリン包接化合物
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE3933027A1 (de) * 1989-09-29 1991-04-11 Schering Ag Kombinationspraeparat mit antithrombotischer wirkung
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5457099A (en) 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
TW254855B (sr) 1993-07-28 1995-08-21 Otsuka Pharma Co Ltd
PL335934A1 (en) * 1997-03-31 2000-05-22 Johnson & Johnson Consumer Solvent system of increased penetration into pharmaceutical compounds
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
AU6023999A (en) * 1998-09-03 2000-03-27 Alcide Corporation Freeze-resistant topical germicides and methods related thereto
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2003030868A1 (en) * 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation

Also Published As

Publication number Publication date
BG66177B1 (bg) 2011-11-30
NO20034705D0 (no) 2003-10-21
CN1512884B (zh) 2010-05-26
PE20021086A1 (es) 2002-12-14
IL158202A (en) 2008-04-13
IS6994A (is) 2003-10-14
CZ20032821A3 (cs) 2004-09-15
AU2002254722B2 (en) 2006-11-09
EP2436384A2 (en) 2012-04-04
US6977257B2 (en) 2005-12-20
EP1381367B1 (en) 2011-12-21
EP2436384B1 (en) 2015-06-10
UA76144C2 (uk) 2006-07-17
EP1381367A1 (en) 2004-01-21
HU230456B1 (hu) 2016-07-28
HUP0303946A3 (en) 2005-06-28
ES2377855T3 (es) 2012-04-02
KR20030096332A (ko) 2003-12-24
HRP20030870B1 (en) 2011-10-31
CA2445276C (en) 2009-10-13
PL364666A1 (en) 2004-12-13
BR0208986A (pt) 2004-04-20
PT1381367E (pt) 2012-03-01
HRP20030870A2 (en) 2004-06-30
BG108216A (bg) 2004-12-30
MXPA03009728A (es) 2004-01-29
HUP0303946A2 (hu) 2004-04-28
CA2445276A1 (en) 2002-10-31
MY129350A (en) 2007-03-30
SK12642003A3 (sk) 2004-07-07
SK287948B6 (sk) 2012-06-04
IS2863B (is) 2013-12-15
NO20034705L (no) 2003-11-28
RS52082B (sr) 2012-06-30
EP2436384B2 (en) 2018-05-23
TWI337865B (en) 2011-03-01
CN1512884A (zh) 2004-07-14
CZ306181B6 (cs) 2016-09-14
EP2436384A3 (en) 2012-09-19
US20020193438A1 (en) 2002-12-19
ATE537831T1 (de) 2012-01-15
UY27273A1 (es) 2002-11-29
EP1381367A4 (en) 2009-07-01
DK1381367T3 (da) 2012-04-10
KR100909329B1 (ko) 2009-07-24
JP4401077B2 (ja) 2010-01-20
EE200300523A (et) 2004-02-16
NO324606B1 (no) 2007-11-26
EE05581B1 (et) 2012-10-15
HK1168792A1 (en) 2013-01-11
NZ528550A (en) 2005-03-24
PL206882B1 (pl) 2010-10-29
RU2003132426A (ru) 2005-04-20
WO2002085366A1 (en) 2002-10-31
ZA200307797B (en) 2004-10-06
YU84703A (sh) 2006-08-17
AR033168A1 (es) 2003-12-03
GEP20053602B (en) 2005-08-10
JP2004532225A (ja) 2004-10-21
HK1058316A1 (en) 2004-05-14
CY1112606T1 (el) 2016-02-10
RU2295960C2 (ru) 2007-03-27

Similar Documents

Publication Publication Date Title
HUP0303946A3 (en) Aripiprazole oral solution
GB0112834D0 (en) Medicaments
AU2002365120A8 (en) Medicaments
GB0102902D0 (en) Medicaments
GB0128415D0 (en) Medicaments
GB0120658D0 (en) Medical aerosols
GB0111579D0 (en) Oral supplement
GB0105469D0 (en) Medicaments
GB0115182D0 (en) Medicaments
GB0124161D0 (en) Medicaments
GB0124538D0 (en) Medicaments
GB0109215D0 (en) Medicaments
GB0125058D0 (en) Medicaments
GB0126637D0 (en) Medicaments
GB0115988D0 (en) Medicaments
GB0124551D0 (en) Medicaments
GB0125057D0 (en) Medicaments
GB0109028D0 (en) Medicaments
GB0105967D0 (en) Medicaments
GB0119030D0 (en) Medicaments
GB0124537D0 (en) Medicaments
GB0125056D0 (en) Medicaments
GB0125233D0 (en) Medicaments
GB0101414D0 (en) Medicaments
GB0106875D0 (en) Medicaments

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed